Archive for the ‘china retractions’ Category
Xia Jiahong, an immunology researcher at Huazhong Science and Technology University in Wuhan, China, who had a paper subject to a fascinating Expression of Concern earlier this month, turns out to have had a few other entries in his retraction and correction record recently.
Here’s a retraction in the January 2014 issue of the Journal of Heart and Lung Transplantation, for “Combined treatment with chemokine receptor 5 blocker and cyclosporine induces prolonged graft survival in a mouse model of cardiac transplantation,” a paper first published in 2010: Read the rest of this entry »
The Journal of Food Science has retracted a 2012 paper by Chinese scientists, one of whom copped to having made up data in the paper — which also plagiarized from a 2009 article by other researchers — and forging his co-authors’ names on the manuscript.
The article, “A Multiplex PCR Assay for the Rapid and Sensitive detection of Methicillin-Resistant Staphylococcus aureus and Simultaneous Discrimination of Staphylococcus aureus from Coagulase-Negative Staphylococci,” appeared online in October 2012 and was written by a group from Northwest A & F University, in Yangling, and Tianshui Normal University.
It has been cited once, according to Thomson Scientific’s Web of Knowledge. From the abstract: Read the rest of this entry »
The paper, “Avian Reovirus Nonstructural Protein p17-Induced G2/M Cell Cycle Arrest and Host Cellular Protein Translation Shutoff Involve Activation of p53-Dependent Pathways,” came from a group at National Pingtung University of Science and Technology, in Pingtung, China. It purported to find that: Read the rest of this entry »
That must have been what happened to a quintet of authors from Shanghai who’ve just had to retract an article from the Journal of Antimicrobial Chemotherapy. Here’s the notice
(sadly, behind a paywall) [see note at end of post] for “Role of clofazimine in the treatment of multidrug-resistant tuberculosis: a retrospective observational cohort assessment:” Read the rest of this entry »
A group of researchers in China has lost a paper on the human microbiome in Frontiers in Cellular and Infection Microbiology for cannibalizing much of it from previously published work by other scientists.
The article, titled “Human gut microbiota: dysbiosis and manipulation,” appeared on Sept. 27, 2012, and was written by a team from the Beijing Genomics Institute-Shenzhen. It has been cited just once, according to Thomson Scientific’s Web of Knowledge, by another paper in the same journal.
A former postdoc at the National Institutes of Health (NIH) committed misconduct in a study of hepatitis by falsely claiming that data from a single trial subject were actually from more than a dozen different people, the Office of Research Integrity (ORI) has found.
The investigation was prompted by allegations made by readers of the paper. Baoyan Xu made what the ORI called “a limited admission” that “some better looking strips were repeatedly used as representatives for several times [sic].”
According to a report of the ORI’s findings to be published in the Federal Register tomorrow, the paper, “Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing, published earlier this year in the Proceedings of the National Academy of Sciences (PNAS): Read the rest of this entry »
The article, “Interaction of Somatostatin Receptor-2 and Neuropeptide Y Receptor-1 in mice dorsal root ganglion neurons on the Pinch-Nerve injury model,” came from a group in Harbin, China, and Frieburg, Germany, and was published in April 2013.
Here are the details. One article, “Chemopreventive effect of dietary glutamine on colitis-associated colon tumorigenesis in mice,” came from a group in China. Published earlier this year, the authors seem to have had some trouble with their figures. As the corrigendum explains: Read the rest of this entry »
Nearly six months after first expressing concern about the validity of a 2010 paper on multiple sclerosis, Nature Medicine has retracted the article for containing “erroneous” data — which in this case don’t seem to have existed, making them more fabricated than wrong.
The paper, “Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease,” came from a group led by Jingwu Zhang, who at the time ran GlaxoSmithKline’s Research and Development Center in Shanghai.